Prostate Cancer
Conditions
Keywords
biomarker
Brief summary
The goal of this translational study is to test the use of biomarkers in salvage treatment for prostate cancer after a previous operation to remove the prostate. The main question it aims to answer is: • Can a biomarker identify a group of patients most likely to benefit from androgen deprivation therapy in conjunction with salvage radiotherapy No new participants will be involved, but tumour samples will be acquired, for patients that gave their permission in the completed RADICALS RT and HD studies.
Detailed description
Early prostate cancer represents a wide spectrum of disease. Indolent disease is unlikely to ever become symptomatic and treatment is needlessly morbid and costly. Aggressive disease warrants intensification of therapy. Current clinical methods are poor at discriminating these outcomes. The RADICALS trial was the largest trial conducted to date in men requiring further curative treatment after an operation. It already defined the role for radiotherapy after surgery (prostatectomy). The standard of care is now for blood test (PSA) monitoring after prostatectomy with radiotherapy offered when the PSA rises. The role and duration of hormone treatment (androgen deprivation), given in combination with radiotherapy, remains less clear. Currently if androgen deprivation is to be given, the RADICALS data support the use of a 24-month course, but this entails a considerable burden of side-effects for patients. Pathological and biological markers are needed to identify those most likely to benefit from androgen deprivation. In RADICALS-TR, the investigators will conduct translational analyses on the biopsy and prostatectomy specimens from the RADICALS trial. The investigators aim to identify prognostic features and biomarkers predictive of benefit from androgen therapy. The investigators will prioritise the refinement and validation of clinical biomarkers already close to clinical utilisation. In this way it is hoped that findings can rapidly translate to stratified clinical trials and improved patient care.
Interventions
DRUGLuteinising Hormone-Releasing Factor Analogue
Androgen Deprivation Therapy
Sponsors
University College, London
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 99 Years
Inclusion criteria
DISEASE CHARACTERISTICS: Inclusion criteria: Diagnosis of nonmetastatic adenocarcinoma of the prostate Must have undergone radical prostatectomy Post-operative serum prostate-specific antigen (PSA) \< 0.4 ng/mL No post-operative biochemical failure, defined as EITHER two consecutive rises in PSA and final PSA \> 0.1 ng/mL OR three consecutive rises in PSA (for patients undergoing hormone therapy duration randomization)
Exclusion criteria
Known distant metastases from prostate cancer PSA \> 5 ng/mL at the time of hormone randomization (for patients undergoing hormone therapy duration randomization) PATIENT CHARACTERISTICS: * No other active malignancy likely to interfere with protocol treatment or follow-up. * Consent has been given within the RADICALS (RT/HD) trial to translational research and follow up. PRIOR CONCURRENT THERAPY: Inclusion criteria: See Disease Characteristics Co-enrollment to other trials is permitted, providing this does not interfere with the outcome measures 5-α reductase inhibitors, soya, selenium, and vitamin E are acceptable non-trial therapies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from Distant Metastases | Up to 12 years | The absence of prostate cancer metastases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Up to 12 years | Freedom from death from any cause |
| Disease Specific Survival | Up to 12 years | Freedom from prostate cancer specific death |
| Freedom from treatment failure | Up to 12 years | Freedom from PSA progression whilst receiving androgen deprivation therapy |
| Clinical Progression Free survival | Up to 12 years | Clinical progression of prostate cancer or initiation of non-protocol hormone therapy or death from prostate cancer. |
| Non protocol hormone therapy | Up to 12 years | Initiation of hormone therapy other than that randomised. |
| Freedom from biochemical progression | Up to 12 years | Where a biochemical progression event is defined as a PSA level of ≥0.4ng/ml following radiotherapy or a PSA level of \> 2.0ng/ml regardless of prior radiotherapy. |
Contacts
Primary ContactMatthew W Fittall, BMBCh PhD
Outcome results
None listed